TLDR
- Berkshire Hathaway has concluded its $9.7 billion acquisition of OxyChem.
- The deal bolsters Berkshire’s chemicals and industrial presence.
- Occidental intends to utilize the proceeds to reduce debt to below $15 billion.
- Greg Abel officially assumes the CEO role in the post-Buffett era.
- Berkshire holds a record cash reserve of $381.7 billion.
Berkshire Hathaway Inc. (BRK-B) stock was trading at $494.06, a 1.71% decline, as the conglomerate confirmed the completion of its $9.7 billion purchase of Occidental Chemical Corporation, commonly known as OxyChem.
The transaction was finalized on January 2, 2026, representing one of Berkshire’s recent major deals and coinciding with the start of its post-Buffett leadership phase.
The all-cash acquisition was first announced in October 2025, with Berkshire agreeing to buy OxyChem from Occidental Petroleum Corporation. Although the purchase price is subject to customary adjustments, Berkshire stated it had sufficient cash on hand to fund the deal and cover all related expenses.
Berkshire / has just closed its $9.7B acquisition of OxyChem , adding a top-3 U.S. chemicals producer to its empire. All real-world essentials with durable cash flows.
Classic Buffett: boring, critical, cash-generating.
— Schaeffer’s Investment Research (@schaeffers)
Details of the OxyChem Acquisition
As per the agreement, an Occidental subsidiary retained OxyChem’s legacy environmental liabilities, while Glenn Springs Holdings continues to manage existing remediation projects for that unit. OxyChem will operate under Berkshire’s ownership with leadership continuity, with Wade Alleman remaining as president and CEO.
The transaction required regulatory approvals and standard closing conditions, all of which were met ahead of the expected fourth-quarter timeline. Barclays Capital served as financial advisor to Occidental, and legal counsel included Cravath, Swaine & Moore for Occidental and Kirkland & Ellis for Berkshire.
For Occidental, the sale represents a balance sheet reset. The company plans to use $6.5 billion of the proceeds to reduce debt, aiming to get principal debt below $15 billion. This move supports Occidental’s efforts to strengthen its financial position after years of significant capital spending.
Strategic Fit for Berkshire Hathaway
OxyChem adds a large-scale chemicals business to Berkshire’s already diverse portfolio, which includes insurance, railroads, energy, manufacturing, and consumer brands. The acquisition aligns with Berkshire’s longstanding strategy of acquiring established, cash-generating businesses with robust market positions.
While Berkshire has reduced its stakes in long-held holdings like Apple and Bank of America, the OxyChem deal highlights that the conglomerate remains willing to invest capital in operating businesses when valuations and strategic fit are aligned.
Despite the transaction’s size, some investors view it as modest relative to Berkshire’s scale. With a market value exceeding $1 trillion and limited opportunities that can materially impact earnings, even multi-billion-dollar acquisitions may not “move the needle” in the short term.
Entering the Post-Buffett Era
The completion of the OxyChem deal occurs as Berkshire transitions leadership. Warren Buffett has handed the CEO role to Greg Abel after six decades at the helm, marking a historic shift for the company. Buffett remains chairman and has stated he plans to stay active in supporting Abel from Berkshire’s Omaha office.
Abel, 63, joined Berkshire in 2000 following the acquisition of MidAmerican Energy, now Berkshire Hathaway Energy. He has overseen non-insurance operations since 2018, providing him with deep familiarity with the company’s extensive business lines.
Market reaction to the transition has been muted. Class B shares edged lower even as broader U.S. equity indexes rose, reflecting investor caution during a symbolic moment for the conglomerate.
Cash Position and Capital Allocation
One of Abel’s key challenges will be capital deployment. As of September 30, Berkshire held $381.7 billion in cash and equivalents, a record level that has sparked debate among shareholders. While the cash provides flexibility and downside protection, it also highlights the scarcity of large, attractive acquisition targets.
Berkshire shares underperformed the S&P 500 in 2025, adding pressure on new leadership to demonstrate that the company can sustain its long-term track record without Buffett as CEO.
Stock Performance Context
As of January 2, 2026, BRK-B shares showed mixed performance across different time frames. The stock saw a 9.55% gain over the past year but lagged the S&P 500. Over five years, BRK-B outperformed the benchmark, reflecting the durability of its diversified model.
For investors, the OxyChem acquisition and leadership transition signal continuity rather than reinvention. Berkshire remains a conservative, cash-rich conglomerate focused on long-term value, even as it navigates a new chapter without the daily leadership of the “Oracle of Omaha.”
